GLP-1 & compounded medication availability in New Jersey (2026)
New Jersey wrote its compounding limits into its own administrative code and holds telehealth prescribing to a higher bar than most states, and an online questionnaire alone cannot start a prescription here. Here is what ships to New Jersey addresses across all ten product lines we track, with the state’s own regulation and statement cited below.
What ships to New Jersey: all ten lines
| Product line | Available in New Jersey? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Ships under a patient-specific prescription after a live telehealth visit. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | National pricing, every dose. |
| NAD+ | Yes | 8–10 business days | Ships from registered partner pharmacies. |
| Sermorelin | Yes | 8–10 business days | Same flow as the other longevity lines. |
| Glutathione | No | N/A | Not in our formulary at this time. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its federal record follows below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Details in its section. |
| KPV | No | N/A | Not carried; our peptide lines ship as injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal facts below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its own federal record appears below. |
A “No” row is information, not an apology. New Jersey facts on this page were last reviewed on November 16, 2026.
Research peptides in New Jersey: BPC-157, TB-500, KPV, Epitalon & MOTS-c
BPC-157, TB-500, Epitalon and MOTS-c ship to New Jersey addresses as compounded injectables, each under a patient-specific prescription issued after a live telehealth evaluation, the encounter format New Jersey requires. KPV does not ship, here or anywhere, because our peptide lines are injectables only. Each section below states that substance’s own federal record, available or not.
BPC-157 in New Jersey
Ships to New Jersey addresses as a compounded injectable on a patient-specific prescription issued after a live telehealth visit. The federal facts below come with it.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in New Jersey
Available to New Jersey addresses as a compounded injectable under a patient-specific prescription. Its federal record is below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in New Jersey
We do not ship KPV to New Jersey, or to any state. Our peptide lines are compounded as injectables, and KPV is not among them.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in New Jersey
In the New Jersey formulary as a compounded injectable on a patient-specific prescription. The federal picture below applies unchanged.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in New Jersey
MOTS-c ships to New Jersey addresses as a compounded injectable on a patient-specific prescription. Read its federal record below on its own terms.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What New Jersey’s pharmacy regulators say about compounded medications
New Jersey stands out in two ways. First, its compounding limits are written into the state’s own administrative code, not just borrowed from federal policy by reference. Second, its telehealth rules are more demanding than most states’ about how a prescription may begin: an online questionnaire alone is not enough. Both points are cited below; neither one changes which of the ten lines on this page ships to New Jersey.
Board regulation N.J.A.C. 13:39-11.25, titled Prohibited Compounding, bars pharmacists from compounding any commercially available drug product unless the product is modified to produce a significant difference for the patient in the prescriber’s professional judgment, or the commercial product is not available through normal distribution channels in time to meet the patient’s needs and the prescriber and patient approve dispensing the compounded version — and it requires the pharmacist to document the reason either way. Source: New Jersey Board of Pharmacy — Statement Concerning Semaglutide Compounding.
The board’s November 6, 2023 Statement Concerning Semaglutide Compounding adds the sourcing floor: no salt form of semaglutide may be used; any API must be pharmaceutical grade, carry a valid certificate of analysis, and come from an establishment registered with FDA under section 510; “research use only” products may not be used in any circumstance; and nonconforming compounding may lead to enforcement action by FDA and/or the board — with the statement noting that drug manufacturers may bring their own legal proceedings on top. Source: New Jersey Board of Pharmacy — Statement Concerning Semaglutide Compounding (Nov. 6, 2023).
New Jersey requires a proper provider-patient relationship before a prescription may issue and does not permit prescribing based solely on answers to an online questionnaire; a real-time telehealth encounter with a New Jersey-licensed provider that meets the standard of care satisfies the requirement. Source: Center for Connected Health Policy (CCHP) Policy Finder.
Out-of-state pharmacies shipping prescriptions to New Jersey patients must register with the board before dispensing into the state. Source: New Jersey Board of Pharmacy.
What this means for a New Jersey patient is mostly about how the encounter starts: OrderlyMeds evaluations are live telehealth visits with a New Jersey-licensed provider, not questionnaire-only flows, so the state’s requirement is the model rather than an obstacle. Fulfillment comes from registered partner pharmacies under a patient-specific prescription with the reason documented, per the regulation cited above. Pricing is national, so New Jersey pays what every state pays.
New Jersey availability FAQs
Is compounded semaglutide available in New Jersey?
Yes. OrderlyMeds ships compounded semaglutide to New Jersey addresses under a patient-specific prescription, with the documentation the state’s compounding regulation requires. New customers start at $74/month for the first two months.
Why does New Jersey care how my telehealth visit happens?
State rules require a genuine provider-patient relationship before any prescription, and a questionnaire by itself is not sufficient. OrderlyMeds evaluations are live telehealth encounters with New Jersey-licensed providers, which is the format the state expects.
Can I get BPC-157 or other research peptides shipped to New Jersey?
Four of the five ship to New Jersey: BPC-157, TB-500, Epitalon and MOTS-c, as compounded injectables on patient-specific prescriptions. KPV does not, because we compound these lines as injectables only. Each one’s own federal record, including FDA’s safety position, is stated in its section above.
How long does delivery to New Jersey take?
The published window is 8–10 business days from signup for New Jersey addresses.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
